| Susanne Morris, AGCNS | |
|
4101 James Casey St Ste 100, Austin, TX 78745-1145 | |
| (512) 447-2202 | |
| (512) 447-5337 |
| Full Name | Susanne Morris |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 8 Years |
| Location | 4101 James Casey St Ste 100, Austin, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003269341 | NPI | - | NPPES |
| 365107703 | Medicaid | TX | |
| 365107704 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | AP131488 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Oncology Pa | 5395658934 | 855 |
News Archive
When San Francisco voters overwhelmingly approved a ballot measure banning the sale of flavored tobacco products in 2018, public health advocates celebrated. After all, tobacco use poses a significant threat to public health and health equity, and flavors are particularly attractive to youth.
As scientists probe and parse the genetic bases of what makes a human a human (or one human different from another), and vigorously push for greater use of whole genome sequencing, they find themselves increasingly threatened by the unthinkable: Too much data to make full sense of.
Significantly more pre-menopausal women with hypoactive sexual desire disorder (HSDD) reported a clinically meaningful improvement in their condition with flibanserin 100mg compared with placebo, according to new research announced today. Flibanserin is an investigational, non-hormonal treatment being developed by Boehringer Ingelheim for pre-menopausal women with HSDD.
Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites.
Elsevier announced today the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas on common management problems in the post-reproductive health of women. The statements cover the management of the menopause in the context of obesity, epilepsy, endometriosis and premature ovarian failure. Each statement has summary recommendations as a quick aid for the busy clinician.
› Verified 7 days ago
| Entity Name | Texas Oncology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811944101 PECOS PAC ID: 5395658934 Enrollment ID: O20031124000323 |
News Archive
When San Francisco voters overwhelmingly approved a ballot measure banning the sale of flavored tobacco products in 2018, public health advocates celebrated. After all, tobacco use poses a significant threat to public health and health equity, and flavors are particularly attractive to youth.
As scientists probe and parse the genetic bases of what makes a human a human (or one human different from another), and vigorously push for greater use of whole genome sequencing, they find themselves increasingly threatened by the unthinkable: Too much data to make full sense of.
Significantly more pre-menopausal women with hypoactive sexual desire disorder (HSDD) reported a clinically meaningful improvement in their condition with flibanserin 100mg compared with placebo, according to new research announced today. Flibanserin is an investigational, non-hormonal treatment being developed by Boehringer Ingelheim for pre-menopausal women with HSDD.
Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites.
Elsevier announced today the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas on common management problems in the post-reproductive health of women. The statements cover the management of the menopause in the context of obesity, epilepsy, endometriosis and premature ovarian failure. Each statement has summary recommendations as a quick aid for the busy clinician.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susanne Morris, AGCNS Po Box 911230, Dallas, TX 75391-1230 Ph: (972) 997-8000 | Susanne Morris, AGCNS 4101 James Casey St Ste 100, Austin, TX 78745-1145 Ph: (512) 447-2202 |
News Archive
When San Francisco voters overwhelmingly approved a ballot measure banning the sale of flavored tobacco products in 2018, public health advocates celebrated. After all, tobacco use poses a significant threat to public health and health equity, and flavors are particularly attractive to youth.
As scientists probe and parse the genetic bases of what makes a human a human (or one human different from another), and vigorously push for greater use of whole genome sequencing, they find themselves increasingly threatened by the unthinkable: Too much data to make full sense of.
Significantly more pre-menopausal women with hypoactive sexual desire disorder (HSDD) reported a clinically meaningful improvement in their condition with flibanserin 100mg compared with placebo, according to new research announced today. Flibanserin is an investigational, non-hormonal treatment being developed by Boehringer Ingelheim for pre-menopausal women with HSDD.
Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites.
Elsevier announced today the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas on common management problems in the post-reproductive health of women. The statements cover the management of the menopause in the context of obesity, epilepsy, endometriosis and premature ovarian failure. Each statement has summary recommendations as a quick aid for the busy clinician.
› Verified 7 days ago
Emily Allen Beddingfield, ACNS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 7000 N Mo Pac Expy. Ste. 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 | |
Ryan Webb, Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 12731 Research Blvd Ste B200, Austin, TX 78759 Phone: 512-407-4088 | |
Mafon Fomujang, NURSE PRACTITIONER Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 2911 Medical Arts St Ste 10, Austin, TX 78705 Phone: 866-473-0663 | |
Carole L George, MSN, BC-ACNS, CDE Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 6500 N Mo Pac Expy, Bldg. 3, Suite 200, Austin, TX 78731 Phone: 512-458-8400 Fax: 512-458-8593 | |
Mrs. Mary Ann Marcella Miranda, APRN, AHCNS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 3200 W Slaughter Ln, C/o West Oaks Rehabilitation And Healthcare Center, Austin, TX 78748 Phone: 512-992-7836 Fax: 512-364-0654 | |
Sarah Granger-glauser, RN, ACNS-BC Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 711f W 38th St, Austin, TX 78705 Phone: 512-660-0195 Fax: 512-452-9171 |